Effect of Adiponectin Genetic Polymorphism on Rosiglitazone Response
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The aims of the present study were to investigate the association between adiponectin gene
polymorphisms and the response to rosiglitazone monotherapy in T2D patients.
A total of 255 T2D patients and 120 health volunteers were enrolled in this study. 42 T2D
patients with -11377(C/G) or +45(T/G) genotypes were selected to administrate orally 4mg
rosiglitazone daily for 12 consecutive weeks.